Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant chemotherapy in 2005: standards and beyond.

M J Piccart1, D de Valeriola, L Dal Lago

  • 1Medical Oncology Clinic, Jules Bordet Institute, Centre des Tumeurs de l'Universite Libre de Bruxelles, Rue Heger-Bordet, 1, 1000-Brussels, Belgium. martine.piccart@bordet.be

Breast (Edinburgh, Scotland)
|September 29, 2005
PubMed
Summary

Newer adjuvant chemotherapy regimens offer superior efficacy but increased toxicity. Evidence suggests chemotherapy benefits vary significantly based on estrogen receptor status, necessitating a re-evaluation of treatment strategies and clinical trial design.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.

ESMO open·2026
Same author

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>†</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer.

ESMO open·2026
Same author

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.

ESMO open·2026
Same author

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study.

ESMO open·2026

Area of Science:

  • Medical Oncology
  • Breast Cancer Research
  • Adjuvant Therapy

Background:

  • The 2003 St. Gallen consensus classified adjuvant chemotherapy (CT) into standard and superior efficacy groups.
  • Superior regimens (e.g., taxane-based) offer greater benefits but involve higher complexity, toxicity, and cost.

Purpose of the Study:

  • To review long-term side effects of superior adjuvant chemotherapy regimens.
  • To summarize 5-year benefits from taxane trials, including sequential FEC-->docetaxel.
  • To discuss the heterogeneity of CT benefits based on tumor estrogen receptor (ER) status.

Main Methods:

  • Review of latest information on long-term side effects.
  • Analysis of 5-year benefit data from taxane trials.
  • Examination of evidence regarding ER status and CT benefit magnitude.

Related Experiment Videos

Main Results:

  • Heterogeneity in CT benefits is strongly linked to tumor ER status.
  • Anthracycline-based CT remains an acceptable standard for many patients.
  • Taxanes are justified for ER-negative/low-ER tumors, HER-2 overexpression, or cardiotoxicity concerns.

Conclusions:

  • A paradigm shift is needed in understanding CT added value and designing adjuvant trials.
  • Current evidence supports anthracycline-based regimens as a standard.
  • Taxane use should be considered more readily in specific patient subgroups with aggressive disease features.